SCHEMBL3471655

SCHEMBL3471655

Oc1ccc(-c2cnc3c(NCc4ccc5c(c4)OCO5)nccn23)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FYN P06241 4/20 0.59
KDM4E B2RXH2 6/20 0.51
ALDH1A1 P00352 6/20 0.51
GAA P10253 5/20 0.51
MAPT P10636 5/20 0.51
HPGD P15428 3/20 0.51
TSHR P16473 3/20 0.51
HSD17B10 Q99714 3/20 0.51
MAPK1 P28482 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
LMNA P02545 1/20 0.51
HTT P42858 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
TTK P33981 4/20 0.49
PDE5A O76074 2/20 0.46
GFER P55789 1/20 0.46
CLK4 Q9HAZ1 3/20 0.46
PIK3CD O00329 1/20 0.44
MEN1 O00255 1/20 0.43
ALOX15 P16050 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12409301 0.92 PDE5A (0.52) FYNKDM4EALDH1A1GAAMAPT
SCHEMBL3469850 0.92 CLK4 (0.51) FYNKDM4EALDH1A1GAAMAPT
SCHEMBL9937912 0.85 TTK (0.72) TTK
SCHEMBL14767510 0.84 ALDH1A1 (0.52) FYNKDM4EALDH1A1GAAMAPT
SCHEMBL3466304 0.82 PDE5A (0.53) FYNKDM4EALDH1A1GAAMAPT
SCHEMBL14668730 0.81 TTK (0.56) TTK
SCHEMBL12409289 0.81 TTK (0.56) FYNTTK
SCHEMBL3469970 0.81 BRAF (0.57) FYNKDM4EALDH1A1GAAMAPT
SCHEMBL12409236 0.81 ALDH1A1 (0.47) KDM4EALDH1A1GAAMAPTHPGD
SCHEMBL12409282 0.80 TTK (0.55) KDM4EALDH1A1GAAMAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010069684-A1 COMPOUNDS FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY BIOMARIN IGA, LTD. (BS) 2010-06-24 WO claimed
US-8362018-B2 Substituted imidazo[1,2-a]pyrazine compounds useful for the treatment of viral infections BIOFOCUS DPI, LTD. (GB) 2013-01-29 US disclosed
US-8362018-B2 Substituted imidazo[1,2-a]pyrazine compounds useful for the treatment of viral infections BIOFOCUS DPI, LTD. (GB) 2013-01-29 US disclosed
US-20110166147-A1 IMIDAZOPYRAZINE COMPOUNDS BIOFOCUS DPI, LTD. (GB) 2011-07-07 US disclosed
US-20110166147-A1 IMIDAZOPYRAZINE COMPOUNDS BIOFOCUS DPI, LTD. (GB) 2011-07-07 US disclosed
WO-2010069684-A1 COMPOUNDS FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY BIOMARIN IGA, LTD. (BS) 2010-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166147-A1 IMIDAZOPYRAZINE COMPOUNDS CYP3A5, HAVCR2, CYP3A43 FYN 3511/4885KDM4E 4116/4885ALDH1A1 750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.